https://www.selleckchem.com/products/pmx-53.html
of a specific radiolabeled antibody and a separation membrane. We demonstrate our system to be comparable to other SARS-CoV-2 detection kits already approved by the FDA and believe this technology could be easily deployed to countries with limited resources for the diagnosis of COVID-19. Furthermore, workflows could be easily adapted to target other antigens and therefore other types of diseases. Here we report the development and validation of a SARS-CoV-2 detection system based on the combination of a specific radiolabeled antibody and
Like
Comment
Share
